Media

Press Kit

Malin Media Pack

> Coming Soon

Reports & Presentations

CEO Letter to Shareholders

> download > go to Reports & Presentations page

Latest Press Releases

RNS Announcements

Investee Companies

Wed, 03 Mar 2021

Notice of Results

Wed, 10 Feb 2021

Result of EGM

Fri, 05 Feb 2021

Immunocore Prices Upsized Nasdaq IPO

Mon, 18 Jan 2021

Immunocore Files for Potential IPO on Nasdaq

Fri, 15 Jan 2021

Notice of EGM

News Archive>

01 Mar 2021

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

24 Feb 2021

Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

19 Feb 2021

Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA

17 Feb 2021

EmitBio Demonstrates Statistically Significant Results in Clinical Trial for COVID-19 Treatment

16 Feb 2021

Immunocore announces key appointments to management and Board

Media Contacts

Malin Media Contact

Tel: +353 (0)1 901 5717

mediarelations@malinplc.com
Ireland - Financial Media Contact

Powerscourt

Tel: +353 (0)1 536 0682

malin@powerscourt-group.com
UK - Financial Media Contact

Consilium Strategic Communications

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com